236 related articles for article (PubMed ID: 19192430)
1. Potential of glucose-lowering drugs to reduce cardiovascular events.
Zarich SW
Curr Diab Rep; 2009 Feb; 9(1):87-94. PubMed ID: 19192430
[TBL] [Abstract][Full Text] [Related]
2. Antidiabetic agents and cardiovascular risk in type 2 diabetes.
Zarich SW
Nat Rev Endocrinol; 2009 Sep; 5(9):500-6. PubMed ID: 19636325
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
[TBL] [Abstract][Full Text] [Related]
4. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
Paneni F; Lüscher TF
Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
[TBL] [Abstract][Full Text] [Related]
6. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
Rahelić D; Javor E; Lucijanić T; Skelin M
Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
Paneni F; Lüscher TF
Am J Cardiol; 2017 Jul; 120(1S):S17-S27. PubMed ID: 28606340
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
Thrasher J
Am J Cardiol; 2017 Jul; 120(1S):S4-S16. PubMed ID: 28606343
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
Tandon N; Ali MK; Narayan KM
Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
[TBL] [Abstract][Full Text] [Related]
10. [Glycemic control and cardiovascular benefit: What do we know today?].
Hanefeld M; Schönauer M; Forst T
Dtsch Med Wochenschr; 2010 Feb; 135(7):301-7. PubMed ID: 20146161
[TBL] [Abstract][Full Text] [Related]
11. Does choice of antidiabetes therapy influence macrovascular outcomes?
Zarich SW
Curr Diab Rep; 2010 Feb; 10(1):24-31. PubMed ID: 20425063
[TBL] [Abstract][Full Text] [Related]
12. Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG.
Tsioufis C; Andrikou E; Thomopoulos C; Papanas N; Tousoulis D
Curr Vasc Pharmacol; 2017; 15(5):457-468. PubMed ID: 27928947
[TBL] [Abstract][Full Text] [Related]
13. Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting.
Bhushan R; Elkind-Hirsch KE; Bhushan M; Butler WJ; Duncan K; Marrioneaux O
Diabetes Technol Ther; 2009 Jun; 11(6):353-9. PubMed ID: 19459763
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes.
Home P
Diabetes Technol Ther; 2012 Jun; 14 Suppl 1():S33-42. PubMed ID: 22650223
[TBL] [Abstract][Full Text] [Related]
15. [Hypoglycemia and cardiovascular risk].
Avogaro A
G Ital Cardiol (Rome); 2014 Dec; 15(12 Suppl 2):4S-12S. PubMed ID: 25623545
[TBL] [Abstract][Full Text] [Related]
16. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
Hemmingsen B; Lund SS; Vaag A
Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
[TBL] [Abstract][Full Text] [Related]
17. Effects of oral antihyperglycemic agents in modifying macrovascular risk factors in type 2 diabetes.
Lebovitz HE
Diabetes Care; 1999 Apr; 22 Suppl 3():C41-4. PubMed ID: 10189561
[TBL] [Abstract][Full Text] [Related]
18. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
19. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
Dailey G
Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
[TBL] [Abstract][Full Text] [Related]
20. EMPA-REG OUTCOME: The Endocrinologist's Point of View.
Perreault L
Am J Cardiol; 2017 Jul; 120(1S):S48-S52. PubMed ID: 28606344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]